Advisory
Committees
Nature and Basis Statements of Conflict(s)
of Interest for Voting Members of FDA Advisory Committee Members
The Agency is revising its procedures
regarding the disclosure of conflicts of interest and waivers for
voting advisory committee members in order to implement the requirements
of section 795 of Pub. L. No. 109-97 (Agriculture, Rural Development,
Food and Drug Administration, and Related Agencies Appropriations
Act, 2006) (Nov. 10, 2005). This information is being provided as
an interim measure to comply with the requirements of this law.
Clinical Pharmacology
Subcommittee Meeting of the Advisory Committee for Pharmaceutical
Science
October 18-19, 2006
Jeffrey Barrett, Ph.D.
• 18 U.S.C. 208 waiver (pdf)
Edmund Capparelli, Pharm.D.
• 18 U.S.C. 208 waiver (pdf)
Marie Davidian, Ph.D.
• 18 U.S.C. 208 waiver (pdf)
Kathleen Giacomini, Ph.D.
• 18 U.S.C. 208 waiver (pdf)
William Jusko, Ph.D.
• 18 U.S.C. 208 waiver (pdf)
Jaap Mandema, Ph.D.
• 18 U.S.C. 208 waiver (pdf)
Jurgen Venitz, M.D.
• 18 U.S.C. 208 waiver (pdf)
Paul Watkins, Ph.D.
• 18 U.S.C. 208 waiver (pdf)
Page updated:
September 27, 2006
|